Hepatic Encephalopathy

Introduction
Hepatic encephalopathy (HE) is a potentially reversible neuropsychiatric syndrome arising from hepatic insufficiency and/or portosystemic shunting. It is a critical clinical landmark in cirrhosis, signifying disease progression and conferring a markedly worsened prognosis, with severe HE associated with over 50% mortality within the first year. HE occurs in 30–50% of patients with cirrhosis during their disease course and presents as a spectrum ranging from subtle cognitive deficits (covert HE) to coma (overt HE).

Learning Objectives

1. Recognize the clinical spectrum of hepatic encephalopathy (HE) from covert to overt presentations and appropriately grade severity using West Haven Criteria.
2. Systematically evaluate altered mental status in cirrhosis patients by identifying common precipitants and excluding alternative diagnoses.
3. Apply evidence-based management strategies including lactulose titration, rifaximin therapy, and treatment of reversible precipitating factors.
4. Recognize HE as a prognostic landmark requiring consideration of liver transplant evaluation and interpret outcome data to guide goals of care discussions.

Pathophysiology

Click the dropdown below if you would like some information on the pathophysiology

Pathophysiology>

• Primary process: Astrocyte dysfunction (Alzheimer type II astrocytosis)

• Central mechanism: Hyperammonemia

  • Gut bacteria produce ammonia from dietary protein.
  • Liver failure and portosystemic shunting → impaired ammonia clearance.
  • Ammonia crosses the blood–brain barrier.
  • Astrocytes convert ammonia + glutamate → glutamine (via glutamine synthetase).
  • Intracellular glutamine accumulation → osmotic astrocyte swelling → low-grade cerebral edema.

• Key amplifying mechanisms:

  • Neuroinflammation: Cytokines (TNF-α, IL-6, IL-17) potentiate ammonia toxicity.
  • Increased GABAergic tone: Neurosteroids (e.g., allopregnanolone) enhance GABA-A receptor activity → neuronal inhibition.
  • Manganese deposition: Basal ganglia accumulation → T2 MRI hyperintensity, parkinsonism.
  • Oxidative/nitrosative stress: Reactive species impair neuronal signaling.

• Acute liver failure:

  • Rapid ammonia elevation (>200 μmol/L) → high risk of severe cerebral edema and herniation.

Classification and Clinical Spectrum

HE is classified by underlying etiology:

• Type A: Acute liver failure.
• Type B: Portosystemic bypass with intact liver.
• Type C: Cirrhosis.

Severity is graded using the West Haven Criteria:

Severity	Description	Category
Grade 0	Minimal HE; not outwardly detectable; deficits only on specialized testing.	Covert
Grade 1	Behavioral changes, impaired attention, no disorientation; minimal to no change in consciousness.	Covert
Grade 2	Lethargy, disorientation, possibly asterixis, inappropriate behavior.	Overt
Grade 3	Marked confusion, incoherent speech, sleeping most of the time but arousable to voice.	Overt
Grade 4	Comatose, unresponsive to pain; may have decorticate or decerebrate posturing.	Overt

Covert HE (grades 0–1) is clinically significant, affecting quality of life and increasing risks of falls, motor vehicle accidents, and hospitalizations despite preserved consciousness.

Diagnosis

HE remains a diagnosis of exclusion. Clinical assessment is based on West Haven Criteria, with grades 2–4 considered overt HE. Disorientation and asterixis are reliable clinical markers for overt HE. For severely altered consciousness, the Glasgow Coma Scale can be utilized.

Covert HE is diagnosed using:

• Psychometric Hepatic Encephalopathy Score: ≥4 SDs below healthy controls on a 5-test battery. More Info
• Animal Naming Test: 15 animals/minute (70% sensitivity, 63% specificity); 10 animals/minute (15% sensitivity, 92% specificity).
• EncephalApp Stroop Test: >198 seconds (80% sensitivity, 61% specificity). Link to Test

Clinical presentations of covert HE include increased falls, poor sleep, irritability, anorexia, and gait disturbance.

Initial Workup

A broad workup is recommended to evaluate for precipitants or alternative causes. Investigations include:

• CBC
• BMP/CMP
• Liver enzymes
• Coagulation studies
• Urinalysis/Urine Culture
• Blood cultures (if concern for infection)
• Medication Review and Urine drug screen/GCMS
• Diagnostic Paracentesis (if ascites)
• Ammonia level: Not routinely recommended; variable and may be elevated in non-HE conditions. However, a low ammonia in a confused/comatose patient strongly suggests an alternative diagnosis.

Identify and treat precipitants:

• Infection: obtain cultures, urinalysis, diagnostic paracentesis (If ascites is present) for spontaneous bacterial peritonitis.
• GI bleeding: check hemoglobin, ask about hematechezia/melena.
• Constipation: last bowel movement?
• Medication non-compliance: are they taking lactulose and/or rifaximin?
• Electrolyte abnormalities: Especially hyponatremia.
• Dehydration
• Acute kidney injury
• TIPS procedures can worsen HE

Brain imaging (CT/MRI) is not routine in recurrent, non-focal presentations but should be considered for:

• First episode of altered mental status.
• Seizures or focal neurological signs.
• Unsatisfactory response to HE therapy.
• History of fall/trauma or headache.

Differential Diagnosis

Alternative and concurrent causes of altered mental status must be considered, including:

• Alcohol intoxication/withdrawal
• Drug-related encephalopathy (benzodiazepines, opioids, psychotropics)
• Sepsis
• Uremia
• Diabetic ketoacidosis/hyperosmolar state.
• Hyponatremia/hypoglycemia.
• Intracranial hemorrhage (especially subdural in coagulopathy).
• Stroke, seizure (non-convulsive status epilepticus).
• Psychiatric disorders (depression, psychosis).
• Wernicke encephalopathy (thiamine deficiency).
• Nutritional deficiencies.
• Other metabolic derangements.

Multiple causes often coexist and synergistically worsen mental status.

Acute Management

Stabilization:

• Protect airway (intubate if GCS ≤8 or inability to protect airway).
• Prevent physical injury.

Identify and treat precipitants:

• Antibiotics for infection (including empiric for SBP if ascites present).
• Blood transfusion/endoscopy for GI bleed.
• Correction of electrolyte abnormalities and hyponatremia.
• Hydration for dehydration/prerenal azotemia.
• Discontinue offending medications.
• Correct constipation.

First-line therapy:

• Lactulose: 60cc x1 --> 20cc every 1-2 hours until BM occurs --> maintenance to achieve 2-3 soft BM per day.
  • Lactulose enema: For patients unable to take oral medications.
  • If they have a dignicare/rectal tube, you can aim for around 700cc of output a day
• Rifaximin: 550 mg PO twice daily
• Nutrition: Protein restriction is NOT recommended ; maintain adequate protein intake (1.2–1.5 g/kg/day) to prevent malnutrition.

Chronic Management and Prevention

• Long-term lactulose therapy: titrate to maintain 2–3 soft stools daily.
• Add rifaximin: 550 mg twice daily for recurrent HE (reduces hospitalization rate and time to recurrence).

EBM - Lactulose Alone EBM - Rifaximin with or without Lactulose

• Address reversible precipitants: Proactive constipation management, avoid hepatotoxic medications and sedatives, prompt infection management, maintain euvolemia and electrolyte balance.
• Nutrition: Maintain protein intake (1.2–1.5 g/kg/day); avoid restriction. EBM
• Screen for covert HE: In all cirrhosis patients due to impact on quality of life, falls, and driving safety.
• Gastroenterology consultation
• Liver transplant evaluation: HE does not preclude transplantation but signals advanced disease.

Prognosis

HE marks a transition to decompensated cirrhosis with poor survival outcomes:

• Transplant-free survival of 0.95 years in patients ≥65 vs 2.5 years in patients <65.EBM
• Survival probability at 28 days: Grade 2 HE 79.8%, Grade 3 74.3%, Grade 4 60.2%. Link
• Complete reversal of HE --> Associated with better survival (HR 0.271). Link
• Covert HE --> Associated with increased hospitalization (47% vs 15%), death (18% vs 3%), motor vehicle crashes (17% vs 3%). Link

Clinical Pearls

• Ammonia level is NOT routinely needed for diagnosis; variable and may be elevated in non-HE conditions. However, normal ammonia in a confused/comatose patient strongly suggests an alternative diagnosis.
• Protein restriction is harmful; maintain adequate protein intake (1.2–1.5 g/kg/day).
• Consider what the precipitant of HE is.
• Covert HE is common and clinically significant; increases falls, crashes, hospitalizations, and mortality even without obvious confusion.
• Combination lactulose + rifaximin is superior to monotherapy; rifaximin reduces hospitalizations and recurrence when added to lactulose.
• HE does not preclude transplant; signals need for evaluation given poor median survival after first overt episode.
• Brain imaging is not routine in recurrent HE with typical presentation; reserve for first episode, focal signs, seizures, or non-response to therapy.
• Disorientation and asterixis have best inter-rater reliability for detecting overt HE clinically.

Summary

Hepatic encephalopathy is a multifactorial, potentially reversible neuropsychiatric syndrome with profound clinical and prognostic implications in cirrhosis. Early recognition, systematic evaluation for precipitants and alternative causes, and evidence-based management—including optimal use of lactulose and rifaximin—are essential. HE marks a transition to decompensated liver disease, necessitating consideration of liver transplantation and goals of care discussions. Screening for covert HE and proactive management of reversible factors are critical to improving outcomes.